Inventiva
IVA
3.37
-0.10
-2.75%
Inventiva
US · IVA
#3421 by market cap
Listed 2020
3.37
-0.10
-2.75%
Live - 5344 symbols - heartbeat 275s ago
· 2026-10-08 08:59
Pre-market
3.30
-1.93%
After-hours
3.37
0.00%
Overnight
3.39
+0.74%
- Market cap
- 794.93M
- P/E (TTM)i
- -5.63
- P/Bi
- 12.02
- EPSi
- -2.13
- Div yieldi
- 0.00%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on IVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.21, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -51.26% YoY
Margins
- Operating margin
- -2,964.15%
- Net margin
- -7,899.58%
Key ratios & quality
- Enterprise valuei
- 623.18M
- Altman Z-Scorei
- -1.21
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.20M | 7.00M | 372.00K | 4.19M | 12.18M | 17.48M | 9.20M | 4.48M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.09M | 5.94M | 8.88M | 11.34M | 15.28M | 15.61M | 17.10M | 53.89M |
| Research & development | 31.76M | 33.79M | 23.72M | 48.45M | 60.47M | 110.01M | 90.88M | 87.04M |
| Operating profit | -30.65M | -29.22M | -26.55M | -51.17M | -56.86M | -102.67M | -93.99M | -132.88M |
| Pretax profit | -33.02M | -30.22M | -33.62M | -49.28M | -54.29M | -109.82M | -183.90M | -354.11M |
| Tax | 0 | 0 | 0 | 364.00K | -20.00K | 607.00K | 313.00K | 22.00K |
| Net profit | -33.02M | -30.22M | -33.62M | -49.64M | -54.27M | -110.43M | -184.21M | -354.14M |
| Basic EPS | -2 | -1 | -1 | -1 | -1 | -2 | -3 | -2 |
| Diluted EPS | -1.61 | -1.28 | -0.99 | -1.27 | -1.31 | -2.43 | -3.08 | -1.90 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 71.63M | 48.88M | 133.00M | 115.58M | 106.38M | 48.19M | 111.51M | 244.47M |
| Cash & ST investments | 56.69M | 35.84M | 113.02M | 95.38M | 87.79M | 26.99M | 96.56M | 230.87M |
| Inventory | 410.00K | 387.00K | 320.00K | 392.00K | 373.00K | 417.00K | 0 | 0 |
| Total assets | 79.81M | 56.96M | 138.92M | 121.99M | 116.00M | 69.56M | 118.97M | 249.51M |
| Total current liabilities | 15.08M | 13.87M | 13.91M | 22.85M | 30.70M | 50.16M | 120.73M | 77.38M |
| Short-term debt | 151.00K | 112.00K | 18.00K | 1.28M | 5.85M | 5.31M | 5.87M | 32.31M |
| Long-term debt | 74.00K | -- | 10.04M | 8.75M | 25.43M | 27.91M | 46.33M | 26.82M |
| Total liabilities | 18,216,000.00 | 15,568,000.00 | 27,708,000.00 | 33,118,000.00 | 70,528,000.00 | 101,592,000.00 | 225,613,000.00 | 278,033,000.00 |
| Total equity | 61.60M | 41.39M | 111.21M | 88.87M | 45.48M | -32.03M | -106.65M | -28.52M |
| Retained earnings | -33.01M | -30.22M | -33.62M | -49.64M | -54.27M | -110.43M | -184.21M | -354.14M |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 48.19M | 28.61M | 111.51M | 172.81M | 244.47M | 245.97M |
| Cash & ST investments | 26.99M | 10.15M | 96.56M | 146.65M | 230.87M | 233.89M |
| Inventory | 417.00K | 393.00K | 0 | -- | 0 | -- |
| Total assets | 69.56M | 39.43M | 118.97M | 178.96M | 249.51M | 251.21M |
| Total current liabilities | 50.16M | 48.15M | 120.73M | 58.46M | 77.38M | 64.59M |
| Short-term debt | 5.31M | 5.73M | 5.87M | 5.53M | 32.31M | 13.31M |
| Long-term debt | 27.91M | 43.54M | 46.33M | 51.60M | 26.82M | 52.99M |
| Total liabilities | 101,592,000.00 | 118,485,000.00 | 225,613,000.00 | 187,863,000.00 | 278,033,000.00 | 192,208,000.00 |
| Total equity | -32.03M | -79.06M | -106.65M | -8.91M | -28.52M | 59.00M |
| Retained earnings | -110.43M | -49.03M | -184.21M | -175.88M | -354.14M | -69.47M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -34.21M | -28.40M | -30.59M | -47.63M | -44.93M | -81.61M | -85.93M | -104.88M |
| Depreciation & amortization | 1.30M | 1.58M | 1.89M | -1.29M | 1.70M | 2.60M | 5.20M | 3.22M |
| Free cash flow | -34.76M | -28.54M | -30.88M | -48.16M | -45.49M | -82.15M | -86.26M | -105.13M |
| Dividends paid | -- | -- | -- | -- | -- | 0 | 0 | 0 |
| Stock buybacks / issuance | 32.53M | 8.65M | 101.78M | 25.48M | 8.83M | 30.59M | 57.34M | 206.44M |
| Ending cash balance | 56.69M | 35.84M | 105.69M | 86.55M | 86.74M | 26.92M | 96.56M | 99.31M |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -53.53 | -58.68 | -44.06 | -49.62 | -80.80 | -1,642.63 | -- | -- |
| ROA %i | -43.61 | -44.19 | -34.33 | -38.05 | -45.61 | -119.02 | -195.42 | -192.22 |
| ROIC %i | -53.35 | -58.79 | -41.50 | -45.00 | -60.30 | -251.11 | -- | -- |
| 5-year avg ROE %i | -28.59 | -37.62 | -42.69 | -49.01 | -57.33 | -375.16 | -- | -- |
| EBIT margin %i | -1,043.45 | -431.75 | -9,019.35 | -1,171.60 | -440.00 | -598.73 | -1,866.96 | -7,150.32 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.75 | 3.53 | 9.56 | 5.06 | 3.47 | 0.96 | 0.92 | 3.16 |
| Quick ratioi | 4.64 | 3.44 | 9.10 | 4.68 | 3.16 | 0.85 | 0.90 | 3.10 |
| Debt / assetsi | 0.28 | 0.20 | 7.24 | 8.30 | 29.75 | 53.89 | 45.67 | 23.99 |
| LT debt / equityi | 0.12 | 0.00 | 9.03 | 9.95 | 63.03 | -- | -- | -- |
| Interest coveragei | -8,339.75 | -10,071.33 | -508.36 | -356.07 | -75.79 | -20.21 | -14.10 | -9.55 |
| Revenue CAGR (3Y) %i | -13.12 | -9.51 | -57.36 | 9.47 | 20.29 | 260.83 | 29.92 | -28.33 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -1,642.63 | -- | -- | -- | -- | -989.03 |
| ROA %i | -119.02 | -189.01 | -195.42 | -284.88 | -192.22 | -115.18 |
| ROIC %i | -251.11 | -- | -- | -- | -- | -255.26 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -598.73 | -608.31 | -1,866.96 | -2,165.17 | -7,150.32 | -426,085.71 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.96 | 0.59 | 0.92 | 2.96 | 3.16 | 3.81 |
| Quick ratioi | 0.85 | 0.43 | 0.90 | 2.90 | 3.10 | 3.78 |
| Debt / assetsi | 53.89 | 133.34 | 45.67 | 31.93 | 23.99 | 26.54 |
| LT debt / equityi | -- | -- | -- | -- | -- | 90.41 |
| Interest coveragei | -20.21 | -11.24 | -14.10 | -17.67 | -9.55 | -5.45 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Service delivery and clinical stage research, notably into potential therapies in the areas of100.00%
Region
China100.00%
Quote time 2026-10-08 08:59:17 · For reference only, not investment advice and not tailored to your situation.